Menu
← Oncology Approval Tracker
FDA DECISION ·
Vidaza
azacitidine · Celgene / Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Newly diagnosed juvenile myelomonocytic leukemia in pediatric patients at least one month old.
LAMPGEN ANALYSIS
Why it matters
The action adds a treatment for a rare childhood leukemia.
What research teams should watch
Confirm pediatric diagnostic criteria and coordinate response assessment with the transplant team.
PRIMARY RECORDS